Significance of Alpha-inhibin Expression in Pheochromocytomas and Paragangliomas.
Journal
The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904
Informations de publication
Date de publication:
01 09 2021
01 09 2021
Historique:
pubmed:
8
4
2021
medline:
25
9
2021
entrez:
7
4
2021
Statut:
ppublish
Résumé
Alpha-inhibin expression has been reported in pheochromocytomas and paragangliomas (PPGLs). We analyzed alpha-inhibin immunohistochemistry in 77 PPGLs (37 pheochromocytomas [PCCs] and 40 paragangliomas) and correlated the results with catecholamine profile, tumor size, Ki-67 labeling index, succinate dehydrogenase B subunit and carbonic anhydrase IX (CAIX) staining, and genetic pathogenesis. PPGLs were classified as pseudohypoxic cluster 1 disease with documented VHL mutation or SDHx mutation or biochemical phenotype, whereas NF1-driven and RET-driven PPGLs and those with a mature secretory (adrenergic or mixed adrenergic and noradrenergic) phenotype were classified as cluster 2 disease. The Cancer Genome Atlas data on INHA expression in PPGLs was examined. Alpha-inhibin was positive in 43 PPGLs (56%). Ki-67 labeling indices were 8.07% and 4.43% in inhibin-positive and inhibin-negative PPGLs, respectively (P<0.05). Alpha-inhibin expression did not correlate with tumor size. Alpha-inhibin was expressed in 92% of SDHx-related and 86% of VHL-related PPGLs. CAIX membranous staining was found in 8 of 51 (16%) tumors, including 1 SDHx-related PCC and all 5 VHL-related PCCs. NF1-driven and RET-driven PPGLs were negative for alpha-inhibin and CAIX. Alpha-inhibin was expressed in 77% of PPGLs with a pseudohypoxia signature, and 20% of PPGLs without a pseudohypoxia signature (P<0.05). PPGLs with a mature secretory phenotype were negative for CAIX. The Cancer Genome Atlas data confirmed higher expression of INHA in cluster 1 than in cluster 2 PPGLs. This study identifies alpha-inhibin as a highly sensitive (90.3%) marker for SDHx/VHL-driven pseudohypoxic PPGLs. Although CAIX has low sensitivity, it is the most specific biomarker of VHL-related pathogenesis. While alpha-inhibin cannot replace succinate dehydrogenase B subunit immunohistochemistry for detection of SDHx-related disease, it adds value in prediction of cluster 1 disease. Importantly, these data emphasize that alpha-inhibin is not a specific marker of adrenal cortical differentiation, as it is also expressed in PCCs.
Identifiants
pubmed: 33826547
doi: 10.1097/PAS.0000000000001715
pii: 00000478-202109000-00012
doi:
Substances chimiques
Biomarkers, Tumor
0
inhibin-alpha subunit
0
Inhibins
57285-09-3
Carbonic Anhydrase IX
EC 4.2.1.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1264-1273Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Références
Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31:1770–1786.
Pamporaki C, Hamplova B, Peitzsch M, et al. Characteristics of pediatric vs adult pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2017;102:1122–1132.
Sbardella E, Cranston T, Isidori AM, et al. Routine genetic screening with a multi-gene panel in patients with pheochromocytomas. Endocrine. 2018;59:175–182.
NGS in PPGL (NGSnPPGL) Study Group, Toledo RA, Burnichon N, Cascon A, et al. Consensus statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. Nat Rev Endocrinol. 2017;13:233–247.
Oudijk L, Gaal J, de Krijger RR. The role of immunohistochemistry and molecular analysis of succinate dehydrogenase in the diagnosis of endocrine and non-endocrine tumors and related syndromes. Endocr Pathol. 2019;30:64–73.
Cascón A, Tennant DA. From transcriptional profiling to tumor biology in pheochromocytoma and paraganglioma. Endocr Pathol. 2012;23:15–20.
Nölting S, Grossman AB. Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies. Endocr Pathol. 2012;23:21–33.
Eisenhofer G, Tischler AS, de Krijger RR. Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification. Endocr Pathol. 2012;23:4–14.
Asa SL, Ezzat S, Mete O. The diagnosis and clinical significance of paragangliomas in unusual locations. J Clin Med. 2018;7:280.
Eisenhofer G, Lenders JW, Timmers H, et al. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem. 2011;57:411–420.
Mete O, Tischler AS, de Krijger R, et al. Protocol for the examination of specimens from patients with pheochromocytomas and extra-adrenal paragangliomas. Arch Pathol Lab Med. 2014;138:182–188.
Fishbein L, Leshchiner I, Walter V, et al. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell. 2017;31:181–193.
Duan K, Mete O. Hereditary endocrine tumor syndromes: the clinical and predictive role of molecular histopathology. AJSP Rev Rep. 2017;22:246–268.
Mete O, Hannah-Shmouni F, Kim R, et al. Asa SL, La Rosa S, Mete O. Inherited neuroendocrine neoplasms. The Spectrum of Neuroendocrine Neoplasia. Cham, Switzerland: Springer; 2021:409–459.
Gill AJ, Benn DE, Chou A, et al. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. Hum Pathol. 2010;41:805–814.
Cheung VKY, Gill AJ, Chou A. Old, new and emerging immunohistochemical markers in pheochromocytoma and paraganglioma. Endocr Pathol. 2018;29:169–175.
Korpershoek E, Favier J, Gaal J, et al. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab. 2011;96:E1472–E1476.
Pinato DJ, Ramachandran R, Toussi ST, et al. Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations. Br J Cancer. 2013;108:429–437.
Favier J, Meatchi T, Robidel E, et al. Carbonic anhydrase 9 immunohistochemistry as a tool to predict or validate germline and somatic VHL mutations in pheochromocytoma and paraganglioma-a retrospective and prospective study. Mod Pathol. 2020;33:57–64.
Romanet P, Guerin C, Pedini P, et al. Pathological and genetic characterization of bilateral adrenomedullary hyperplasia in a patient with germline MAX mutation. Endocr Pathol. 2017;28:302–307.
Udager AM, Magers MJ, Goerke DM, et al. The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes. Hum Pathol. 2018;71:47–54.
Castro-Vega LJ, Buffet A, De Cubas AA, et al. Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Hum Mol Genet. 2014;23:2440–2446.
Gucer H, Szentgyorgyi E, Ezzat S, et al. Inhibin-expressing clear cell neuroendocrine tumor of the ampulla: an unusual presentation of von Hippel-Lindau disease. Virchows Arch. 2013;463:593–597.
Sinkre PA, Murakata L, Rabin L, et al. Clear cell carcinoid tumor of the gallbladder: another distinctive manifestation of von Hippel-Lindau disease. Am J Surg Pathol. 2001;25:1334–1339.
Elmoneim HM, Samaka RM, Ali H. Diagnostic role of inhibin α-subunit and inhibin/activin β-subunit in adrenal cortical and medullary tumors in Egyptian patients. Appl Immunohistochem Mol Morphol. 2012;20:462–469.
Cho EY, Ahn GH. Immunoexpression of inhibin alpha-subunit in adrenal neoplasms. Appl Immunohistochem Mol Morphol. 2001;9:222–228.
Pelkey TJ, Frierson HF Jr, Mills SE, et al. The alpha subunit of inhibin in adrenal cortical neoplasia. Mod Pathol. 1998;11:516–524.
Sangoi AR, McKenney JK. A tissue microarray-based comparative analysis of novel and traditional immunohistochemical markers in the distinction between adrenal cortical lesions and pheochromocytoma. Am J Surg Pathol. 2010;34:423–432.
Zhang PJ, Genega EM, Tomaszewski JE, et al. The role of calretinin, inhibin, melan-A, BCL-2, and C-kit in differentiating adrenal cortical and medullary tumors: an immunohistochemical study. Mod Pathol. 2003;16:591–597.
McCluggage WG, Burton J, Maxwell P, et al. Immunohistochemical staining of normal, hyperplastic, and neoplastic adrenal cortex with a monoclonal antibody against alpha inhibin. J Clin Pathol. 1998;51:114–116.
Păun D, Neamţu MC, Avramescu ET, et al. Inhibin alpha-subunit, Melan A and MNF116 in pheochromocytomas. Rom J Morphol Embryol. 2014;55:905–908.
Arola J, Liu J, Heikkilä P, et al. Expression of inhibin alpha in adrenocortical tumours reflects the hormonal status of the neoplasm. J Endocrinol. 2000;165:223–229.
Ramsay JA, Asa SL, van Nostrand AW, et al. Lipid degeneration in pheochromocytomas mimicking adrenal cortical tumors. Am J Surg Pathol. 1987;11:480–486.
Koch CA, Mauro D, Walther MM, et al. Pheochromocytoma in von Hippel-Lindau disease: distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2. Endocr Pathol. 2002;13:17–27.
Colaprico A, Silva TC, Olsen C, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44:e71.
Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139–140.
Hofland J, van Nederveen FH, Timmerman MA, et al. Expression of activin and inhibin subunits, receptors and binding proteins in human pheochromocytomas: a study based on mRNA analysis and immunohistochemistry. Clin Endocrinol (Oxf). 2007;66:335–340.
Mete O, Asa SL, Giordano TJ, et al. Immunohistochemical biomarkers of adrenal cortical neoplasms. Endocr Pathol. 2018;29:137–149.
Duan K, Gucer H, Kefeli M, et al. Immunohistochemical analysis of the metabolic phenotype of adrenal cortical carcinoma. Endocr Pathol. 2020;31:231–238.
Macklin PS, Yamamoto A, Browning L, et al. Recent advances in the biology of tumour hypoxia with relevance to diagnostic practice and tissue-based research. J Pathol. 2020;250:593–611.
Shankavaram U, Fliedner SM, Elkahloun AG, et al. Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas. Neoplasia. 2013;15:435–447.
Fliedner SM, Shankavaram U, Marzouca G, et al. Hypoxia-inducible factor 2α mutation-related paragangliomas classify as discrete pseudohypoxic subcluster. Neoplasia. 2016;18:567–576.
Amorim-Pires D, Peixoto J, Lima J. Hypoxia pathway mutations in pheochromocytomas and paragangliomas. Cytogenet Genome Res. 2016;150:227–241.
Remacha L, Pirman D, Mahoney CE, et al. Recurrent germline DLST mutations in individuals with multiple pheochromocytomas and paragangliomas. Am J Hum Genet. 2019;104:651–664.
Letouzé E, Martinelli C, Loriot C, et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell. 2013;23:739–752.
Martins RG, Gonçalves LG, Cunha N, et al. Metabolomic urine profile: searching for new biomarkers of SDHx-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2019;104:5467–5477.
Imperiale A, Moussallieh FM, Roche P, et al. Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications. Neoplasia. 2015;17:55–65.
Richter S, Peitzsch M, Rapizzi E, et al. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency. J Clin Endocrinol Metab. 2014;99:3903–3911.
Wallace PW, Conrad C, Brückmann S, et al. Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas. J Pathol. 2020;251:378–387.
Lopez-Jimenez E, Gomez-Lopez G, Leandro-Garcia LJ, et al. Research resource: transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol. 2010;24:2382–2391.
Alam H, Maizels ET, Park Y, et al. Follicle-stimulating hormone activation of hypoxia-inducible factor-1 by the phosphatidylinositol 3-kinase/AKT/Ras homolog enriched in brain (Rheb)/mammalian target of rapamycin (mTOR) pathway is necessary for induction of select protein markers of follicular differentiation. J Biol Chem. 2004;279:19431–19440.
Depoix CL, de Selliers I, Hubinont C, et al. HIF1A and EPAS1 potentiate hypoxia-induced upregulation of inhibin alpha chain expression in human term cytotrophoblasts in vitro. Mol Hum Reprod. 2017;23:199–209.
Cassol C, Mete O. Endocrine manifestations of von Hippel-Lindau disease. Arch Pathol Lab Med. 2015;139:263–268.
Turchini J, Gill AJ. Morphologic clues to succinate dehydrogenase (SDH) deficiency in pheochromocytomas and paragangliomas. Am J Surg Pathol. 2020;44:422–424.
Castelblanco E, Santacana M, Valls J, et al. Usefulness of negative and weak-diffuse pattern of SDHB immunostaining in assessment of SDH mutations in paragangliomas and pheochromocytomas. Endocr Pathol. 2013;24:199–205.
Santi R, Rapizzi E, Canu L, et al. Potential pitfalls of SDH immunohistochemical detection in paragangliomas and phaeochromocytomas harbouring germline SDHx gene mutation. Anticancer Res. 2017;37:805–812.
Sato H, Inomoto C. Positive immunostaining for succinate dehydrogenase B (SDHB) in paraganglioma associated with germline mutation of SDHB, L157X and P236S. Tokai J Exp Clin Med. 2020;45:148–151.
Papathomas TG, Oudijk L, Persu A, et al. SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). Mod Pathol. 2015;28:807–821.